Compliance in an Outsource Manufacturing Model: What to Look For - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compliance in an Outsource Manufacturing Model: What to Look For
The authors provide detailed lists of important checkpoints to consider when selecting an outsourcing provider.


Pharmaceutical Technology


Equipment

  • Are all critical support systems (e.g., water for injection, nitrogen, clean compressed air, clean steam, equipment cleaning, vial washing, closure processing) validated?
  • Is each idle piece of equipment clearly marked "needs cleaning" or "cleaned, ready for service"?
  • Is idle equipment stored in a designated area?
  • Are there operational SOPs for instruments?
  • Are written procedures available for each piece of equipment used in the testing or holding of components, in-process material or drugs?
  • Are all pieces of equipment clearly identified with easily visible markings?
  • Are all pieces of equipment also marked with an identification number that corresponds with an entry in an equipment log?
  • Does each piece of equipment have written instructions for maintenance that includes a schedule for maintenance?
  • Is there a maintenance log for each piece of equipment?
  • Are there use logs for all analytical equipment?
  • Are written procedures established for the cleaning and maintenance of equipment and utensils (e.g., autoclave, oven, tanks)?
  • Has a written schedule been established and is it followed for equipment cleaning?
  • Are written records maintained on equipment cleaning, sanitizing, and maintenance on or near each piece of equipment?
  • Does the facility have approved written procedures for checking and calibrating each piece of measurement equipment?
  • Is all instrumentation installed and qualified (installation qualification, operational qualification, and performance qualification, IQ/OQ/PQ) with supporting documentation?
  • Is there a program for qualifying equipment? Have all appropriate pieces of equipment been validated?
  • When computers are used to automate production or quality testing, have the computer and software been validated?

Organized sample storage, material and component control

Laboratory samples

  • Are samples collected and identified properly and according to SOPs?
  • Is the receipt, storage, handling, inventorying and disposing of samples adequately tracked?
  • Is chain-of-custody maintained?
  • Does the laboratory have the facility and controls to ensure proper storage of samples under appropriate conditions (e.g., refrigeration) from the time of receipt to disposition?
  • Is there a procedure for reserve and retention samples?
  • Is this procedure followed?

Laboratory chemicals, solutions, and reagents

  • Are all containers identified?
  • Is there an expiration or retest date on each container based on manufacturer information or stability data?
  • Do standardized volumetric solutions, reagents, and solutions have reference to notebook on preparation?

Standards, testing, and methods

  • Are standard solutions and reagents properly handled?
  • Is there adequate expression and recording of laboratory measurements (e.g., procedures for data rounding and averaging)?
  • Is there proper handling, qualification, and requalification of reference standards?
  • Is there testing and monitoring of process water (e.g., water for injection as well as deionized and USP water)?
  • Is there adequate handling of modifications to analytical methods?
  • Are there procedures for the formalization of analytical methods?
  • Are there procedures for interlaboratory methods transfer and qualification?
  • Are there procedures for resampling, retesting, and rechromatography?


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here